Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EPIVER: Intracoronary Epinephrine and Verapamil in Refractory No-reflow Phenomenon in STEMI
NCT04573751Completed
- Sponsor
- Tomsk National Research Medical Centre of the Russian Academy of Sciences
- Start
- Dec 2020
- Primary completion
- Jan 2023
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Randomised trial of epinephrine and verapamil in ST elevation myocardial infarction (STEMI) and no-reflow phenomenon (4 arms), sponsored by Tomsk National Research Medical Centre of the Russian Academy of Sciences. Primary endpoints: Mortality at 1 month and New onset or worsening acute heart failure at 1 month. Started Dec 2020; status: completed.
02
Drugs
epinephrineverapamil
03
Conditions
ST elevation myocardial infarction (STEMI)no-reflow phenomenon
Beyond the preview
Go deeper on NCT04573751.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04573751.